In an interview with Pharmacy Times®, Paul Edison, MBBS, PhD, FRCPI, professor of neurology at Imperial College London, discusses the potential of GLP-1 analogs in treating Alzheimer disease (AD), highlighting their unique ability to target multiple pathological processes, including tau formation, insulin resistance, and synaptic dysfunction.

Full Story